| P50 | author | Matthew N Hurley | Q57565689 |
| | Andrew P Prayle | Q58881618 |
| P2093 | author name string | Patrick Flume | |
| P2860 | cites work | Single versus combination intravenous antibiotic therapy for people with cystic fibrosis | Q24194967 |
| | Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis | Q24200604 |
| | Duration of intravenous antibiotic therapy in people with cystic fibrosis | Q24202855 |
| | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis | Q24240388 |
| | Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis | Q71629320 |
| | Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis | Q71786937 |
| | [Economic aspects in treatment of cystic fibrosis with chronic pulmonary pseudomonas infection. Ambulatory intravenous therapy in comparison with inpatient treatment] | Q74103246 |
| | Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime | Q74523219 |
| | [Ambulatory vs. inpatient intravenous antibiotic therapy in mucoviscidosis patients--a controlled study] | Q74634519 |
| | Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis | Q77222399 |
| | [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis] | Q77402037 |
| | Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? | Q80050474 |
| | Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis | Q80980323 |
| | Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis | Q85155745 |
| | Ceftazidime in patients with pseudomonas infections | Q54495367 |
| | Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis | Q54498316 |
| | Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo | Q54501407 |
| | Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis | Q61912446 |
| | Acute pulmonary exacerbations in cystic fibrosis. A double-blind trial of tobramycin and placebo therapy | Q67252347 |
| | Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone | Q67285211 |
| | Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients | Q67992228 |
| | Aerosol scintigraphy in the assessment of therapy for cystic fibrosis | Q68095176 |
| | [Intravenous administration of antibiotics at home in patients with cystic fibrosis improves quality of life] | Q68134669 |
| | Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease | Q68163093 |
| | Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis | Q68205329 |
| | Tolerance and safety of ciprofloxacin in paediatric patients | Q68687338 |
| | Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis | Q68955379 |
| | Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis | Q69035811 |
| | Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication | Q69238726 |
| | Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin | Q69255054 |
| | Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection | Q69671407 |
| | Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. British Thoracic Society Research Committee | Q69867654 |
| | Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin | Q69888145 |
| | The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: a controlled study | Q69919517 |
| | Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis | Q70113968 |
| | A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis | Q70161420 |
| | Comparative efficacy and tolerance study of azlocillin and carbenicillin in patients with cystic fibrosis: a double blind study | Q70282593 |
| | Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response | Q70282699 |
| | Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis | Q70282708 |
| | Experience with ceftazidime in cystic fibrosis | Q70282714 |
| | Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis | Q70438995 |
| | Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis | Q70521059 |
| | [Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration] | Q70591780 |
| | Pharmacokinetics of once-daily versus thrice daily tobramycin in cystic fibrosis patients | Q71338545 |
| | Measuring inconsistency in meta-analyses | Q27860655 |
| | The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel | Q28270334 |
| | Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients | Q28325196 |
| | Sensitization to aztreonam and cross-reactivity with other beta-lactam antibiotics in high-risk patients with cystic fibrosis | Q28334722 |
| | Cefsulodin sodium therapy in cystic fibrosis patients | Q30451333 |
| | Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data | Q31049430 |
| | Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. | Q33633034 |
| | Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection | Q33650377 |
| | Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. | Q33725822 |
| | Pharmacokinetics of ciprofloxacin in cystic fibrosis | Q33741046 |
| | Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation | Q33744911 |
| | Minimisation of aminoglycoside toxicity in patients with cystic fibrosis | Q33775991 |
| | Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. | Q34098657 |
| | Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group | Q34290556 |
| | Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience | Q34307354 |
| | Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age. | Q34324105 |
| | Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis | Q35065732 |
| | Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis | Q35255315 |
| | Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis | Q35259780 |
| | Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis | Q35532709 |
| | Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. | Q35539743 |
| | Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis | Q35563227 |
| | The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis | Q35627870 |
| | Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis | Q36136038 |
| | Survey of acute renal failure in patients with cystic fibrosis in the UK. | Q36225726 |
| | Ciprofloxacin: comparative data in cystic fibrosis | Q36464503 |
| | Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis | Q36771148 |
| | A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients | Q37185481 |
| | Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis | Q37333080 |
| | Quantitative analysis of the human airway microbial ecology reveals a pervasive signature for cystic fibrosis | Q37502050 |
| | Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations | Q37591703 |
| | Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials | Q37887195 |
| | Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial | Q38488018 |
| | Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group | Q38505793 |
| | Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis | Q38921233 |
| | Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal | Q39820716 |
| | Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients | Q40284573 |
| | A comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli | Q40380967 |
| | Safety of bronchoalveolar lavage in young children with cystic fibrosis | Q40410131 |
| | Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. | Q40788262 |
| | Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis | Q40789277 |
| | Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia | Q40835202 |
| | Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis | Q40835273 |
| | Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis. | Q40856873 |
| | Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin | Q41221196 |
| | Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients | Q41474199 |
| | An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients | Q42058123 |
| | Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs | Q42200170 |
| | Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis | Q43276197 |
| | Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients | Q43276198 |
| | Continuous infusion of ceftazidime in cystic fibrosis | Q43522441 |
| | Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis | Q43525951 |
| | Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis | Q43574441 |
| | Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study | Q43599722 |
| | Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? | Q43607414 |
| | Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis | Q43754593 |
| | Once-daily tobramycin in the treatment of adult patients with cystic fibrosis | Q43897091 |
| | Comparative yearly growth rate of children with mucoviscidosis treated and not treated with ciprofloxacin:clinicomorphological comparisons | Q43907321 |
| | Use of ciprofloxacin in cystic fibrosis patients | Q43922470 |
| | Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis | Q43989705 |
| | Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients | Q44067245 |
| | Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis | Q44161000 |
| | Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis | Q44248035 |
| | Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis | Q44324948 |
| | Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis | Q44359710 |
| | Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? | Q44379999 |
| | Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis | Q44603672 |
| | A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis | Q44732587 |
| | Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis | Q45031290 |
| | Anti-pseudomonas activity of azlocillin during pulmonary infection in patients with cystic fibrosis | Q45220191 |
| | Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs? | Q45262876 |
| | Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial | Q45262881 |
| | Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Cystic Fibrosis Study Group | Q46658825 |
| | The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis | Q46763845 |
| | Relationship between rates of antimicrobial consumption and the incidence of antimicrobial resistance in Staphylococcus aureus and Pseudomonas aeruginosa isolates from 47 French hospitals | Q46906475 |
| | Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin | Q46984010 |
| | Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis | Q47746290 |
| | Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial | Q47751601 |
| | Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. | Q51449327 |
| | Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. | Q52525472 |
| | Pharmaceutical intervention in the care of cystic fibrosis patients. | Q52541814 |
| | Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. | Q53456951 |
| | Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. | Q54131581 |
| | Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. | Q54168335 |
| | The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. | Q54399290 |
| | Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. | Q54404421 |
| | Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin. | Q54437947 |
| | Comparison of cefoperazone sodium vs methicillin, ticarcillin, and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. | Q54452683 |
| P433 | issue | 7 | |
| P921 | main subject | antibiotic | Q12187 |
| | cystic fibrosis | Q178194 |
| P304 | page(s) | CD009730 | |
| P577 | publication date | 2015-07-30 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis | |